dynorphin 1-13
Peptideexperimental
Dynorphin A is a dynorphin, an endogenous opioid peptide that activates the κ-opioid receptor. Its amino acid sequence is Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys (YGGFLRRIRPKLK), a tridecapeptide. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1994 (NCT00000244)
Timeline
1990s
- Jan 1, 1994
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Delta opioid receptorAGONIST
OPRD1 agonist
- Kappa opioid receptorAGONIST
OPRK1 agonist
- Mu opioid receptorAGONIST
OPRM agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDynorphin A ↗
Also known as
- dynorphin 1-13
- dynorphin 1-13
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000244 | Phase 2 | Aug 1, 1994 | National Institute on Drug Abuse (NIDA), University of Minnesota |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 1994 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 1994 |
2 organizations
Page 1 / 1